FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 341 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Living With Metastatic Breast Cancer: How I Reinvented Myself October 30, 2020 The path to least resistance: How our researchers are outsmarting cancer’s... May 25, 2022 How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... October 12, 2023 Load more HOT NEWS Qué debe saber sobre las pruebas de ADN en el hogar... ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March EMA Recommends Extension of Therapeutic Indications for Trifluridine/Tipiracil Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad...
